# Locally Advanced NSCLC: Concurrent Chemoradiation and Consolidation Immunotherapy

## Overview

Stage III non-small cell lung cancer (NSCLC), also known as locally advanced NSCLC, represents a heterogeneous group of tumors that account for approximately 25-30% of all NSCLC cases. The current standard of care for these patients involves concurrent chemoradiation therapy (CRT) followed by consolidation immunotherapy with durvalumab, an anti-PD-L1 agent, a treatment approach often referred to as the PACIFIC paradigm. The Radiation Therapy Oncology Group (RTOG) 0617 trial established 60 Gy as the standard radiation dose, demonstrating that dose escalation to 74 Gy was actually harmful. With the combination of concurrent CRT and durvalumab consolidation, five-year overall survival rates have improved significantly, reaching approximately 40-45%, which is a major advancement compared to historical outcomes of CRT alone, where five-year survival was around 15-20%. Radiation planning in this setting requires careful balancing of adequate tumor coverage while respecting dose constraints to the lungs and heart to minimize toxicity.

## Staging and Patient Selection

### Stage III Subgroups

Stage III NSCLC is subdivided into IIIA, IIIB, and IIIC based on tumor size and nodal involvement. Stage IIIA includes tumors classified as T1-2N2, T3N1, or T4N0-1. Stage IIIB encompasses T1-2N3 and T3-4N2 tumors, while stage IIIC refers to T3-4N3 disease. The primary population for definitive concurrent CRT is patients with unresectable stage III disease. However, some patients with potentially resectable IIIA disease, particularly those with single-station N2 nodal involvement, may be considered for neoadjuvant therapy followed by surgery. This decision requires multidisciplinary discussion to weigh the benefits of surgery versus definitive CRT.

### Patient Selection for Concurrent CRT

Patients selected for concurrent CRT typically have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, indicating they are fully active or restricted in physically strenuous activity but ambulatory. Adequate pulmonary function is essential, with forced expiratory volume in one second (FEV1) greater than 1.0 liter or more than 40% of predicted values. Significant cardiac disease that would preclude treatment must be absent. The tumor should be encompassed within a radiation field that meets lung and cardiac dose constraints to minimize toxicity. Additionally, patients should have experienced less than 10% weight loss over the prior three months to ensure adequate nutritional status.

## Landmark Clinical Trials

### RTOG 0617 (Bradley et al., 2015; 2020 update)

The RTOG 0617 trial was a phase III study with a 2x2 factorial design comparing radiation doses of 60 Gy versus 74 Gy, with or without the addition of cetuximab, in patients receiving concurrent carboplatin and paclitaxel chemotherapy followed by consolidation chemotherapy. The results showed that the higher radiation dose of 74 Gy was associated with worse overall survival, with a median survival of 20.3 months compared to 28.7 months in the 60 Gy arm (hazard ratio [HR] 1.38, p=0.004). Importantly, dose escalation did not improve local tumor control. The study also identified heart dose as an independent predictor of worse survival, with higher volumes of the heart receiving low (V5) and moderate (V30) radiation doses correlating with increased mortality. Cetuximab provided no survival benefit. This trial established 60 Gy as the standard radiation dose and underscored the critical importance of minimizing cardiac radiation exposure.

### PACIFIC Trial (Antonia et al., 2017; 2021 5-year update)

The PACIFIC trial was a phase III study evaluating consolidation durvalumab versus placebo in patients with unresectable stage III NSCLC who had completed concurrent CRT without disease progression. Durvalumab was administered intravenously at 10 mg/kg every two weeks for up to 12 months. Key eligibility criteria included no progression after CRT and initiation of durvalumab within 1 to 42 days of completing CRT. At five years, the median overall survival was 47.5 months in the durvalumab group compared to 29.1 months in the placebo group. The five-year overall survival rates were 42.9% versus 33.4%, respectively (HR 0.72), and progression-free survival at five years was 33.1% versus 19.0%. Grade 3-4 pneumonitis occurred in 3.4% of patients receiving durvalumab compared to 2.6% in the placebo arm. Subgroup analysis suggested that patients with PD-L1 expression below 1% did not clearly benefit, though this finding remains controversial and was derived post hoc. The PACIFIC trial is considered practice-changing, establishing durvalumab as the standard consolidation therapy following concurrent CRT.

### INT 0139 (Albain et al., 2009)

The INT 0139 trial compared concurrent CRT followed by surgery versus concurrent CRT alone in patients with stage IIIA N2 NSCLC. Radiation doses were 45 Gy in the surgery arm and 61 Gy in the CRT-alone arm. The surgery arm experienced higher treatment-related mortality, particularly among patients undergoing pneumonectomy, which had a 26% mortality rate. There was no significant difference in overall survival between the two arms, although progression-free survival favored the surgery group. Subgroup analysis revealed that patients who underwent lobectomy had better overall survival, whereas those who required pneumonectomy had worse outcomes. These findings support selective use of surgery in stage IIIA-N2 patients when lobectomy is feasible.

## Radiation Therapy Technique

### Dose and Fractionation

The standard radiation dose for locally advanced NSCLC is 60 Gy delivered in 30 fractions of 2 Gy each over six weeks. Escalation to 74 Gy is contraindicated based on RTOG 0617 results showing harm. Radiation should begin concurrently with chemotherapy, typically on the first day of the first chemotherapy cycle.

### Target Volume Delineation

Gross tumor volume (GTV) includes the primary tumor and involved lymph nodes identified on computed tomography (CT) and positron emission tomography-computed tomography (PET-CT). PET-CT is mandatory for accurate staging and target delineation. Nodes with standardized uptake values (SUV) of 2.5 or greater should be included in the GTV, and biopsy confirmation of equivocal nodes is recommended when feasible. The clinical target volume (CTV) is defined as the GTV plus a 5-8 mm margin around the primary tumor, respecting anatomic boundaries. Elective nodal irradiation (ENI) is not recommended; instead, involved-field radiation therapy (IFRT) is standard, as used in RTOG 0617. IFRT results in low rates of elective nodal failure (less than 5%) and reduces radiation exposure to lungs and heart. The planning target volume (PTV) is the CTV plus an additional 5-10 mm margin, adjusted based on institutional image-guided radiation therapy (IGRT) protocols and motion management strategies. Four-dimensional CT (4D-CT) is used to assess tumor motion, and an internal target volume (ITV) approach is applied for mobile tumors.

### Organs at Risk Constraints

Dose constraints for organs at risk are critical to minimize toxicity. For the bilateral lungs (excluding the GTV), the volume receiving 20 Gy or more (V20) should be kept at or below 35%, ideally under 30%, with a mean lung dose of 20 Gy or less, preferably under 18 Gy. The esophagus should have a mean dose of 34 Gy or less, with less than 17% of its volume receiving 60 Gy or more, as higher doses correlate with grade 3 or greater esophagitis. The heart constraints include V30 ≤46%, V40 ≤24%, and a mean heart dose of 20 Gy or less, with efforts to minimize cardiac dose as much as possible due to its association with survival. The spinal cord maximum dose should not exceed 45 Gy, ideally kept under 40 Gy when accounting for planning risk volumes (PRV). The brachial plexus maximum dose should be limited to 66 Gy.

| Organ at Risk | Constraint | Ideal Goal | Clinical Concern |
|---|---|---|---|
| Bilateral lung (minus GTV) | V20 ≤ 35%; MLD ≤ 20 Gy | V20 < 30%; MLD < 18 Gy | Pneumonitis (grade ≥ 2) |
| Esophagus | Mean ≤ 34 Gy; V60 < 17% | Minimize length in field | Grade 3+ esophagitis |
| Heart | V30 ≤ 46%; V40 ≤ 24%; Mean ≤ 20 Gy | Minimize as much as possible | Independent OS predictor (RTOG 0617) |
| Spinal cord | Dmax ≤ 45 Gy | < 40 Gy (with PRV) | Myelopathy |
| Brachial plexus | Dmax ≤ 66 Gy | — | Plexopathy |

### IMRT/VMAT vs. 3D-CRT

Intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) have become preferred techniques over three-dimensional conformal radiation therapy (3D-CRT) for locally advanced NSCLC. Secondary analysis of RTOG 0617 demonstrated that IMRT was associated with lower rates of grade 3 or higher pneumonitis compared to 3D-CRT. VMAT offers improved target conformality and reduces lung V20, mean lung dose, and cardiac dose. Daily image guidance with cone-beam CT (CBCT) is standard to ensure accurate treatment delivery.

## Concurrent Chemotherapy

### Standard Regimens

Two chemotherapy regimens are commonly used concurrently with radiation. The cisplatin/etoposide regimen involves cisplatin 50 mg/m² administered on days 1, 8, 29, and 36, combined with etoposide 50 mg/m² on days 1-5 and 29-33. The carboplatin/paclitaxel regimen, as used in RTOG 0617, consists of carboplatin dosed to an area under the curve (AUC) of 2 plus paclitaxel 50 mg/m² weekly during radiation therapy. Both regimens are acceptable, though carboplatin/paclitaxel is more commonly used in the United States. Consolidation chemotherapy after CRT and before durvalumab is not standard practice and has largely been replaced by durvalumab consolidation.

### Durvalumab Consolidation

Durvalumab consolidation should be initiated within 1 to 42 days after completing CRT, following the PACIFIC trial protocol, and continued for up to 12 months. Exploratory analyses suggest that earlier initiation, within 14 days, may be associated with improved outcomes. Patients receiving durvalumab require monitoring for immune-related adverse events, including pneumonitis, hepatitis, colitis, thyroiditis, and dermatitis. Management of pneumonitis involves holding durvalumab for grade 2 toxicity and permanently discontinuing it for grade 3 or 4 pneumonitis.

## Toxicity Management

### Radiation Pneumonitis

Radiation pneumonitis of grade 2 or higher occurs in approximately 15-30% of patients receiving CRT alone, with a modest increase in incidence when durvalumab is added (3.4% grade 3-4 pneumonitis). Risk factors include lung V20 exceeding 35%, mean lung dose above 20 Gy, tumors located in the lower lobes, and pre-existing interstitial lung disease. Pneumonitis typically develops between one and six months after radiation therapy. Treatment consists of corticosteroids, usually prednisone at 1 mg/kg with a slow taper over 4 to 8 weeks.

### Radiation Esophagitis

Grade 3 or higher radiation esophagitis occurs in 5-20% of patients undergoing concurrent CRT. Risk factors include the esophageal volume receiving 60 Gy and the length of esophagus included in the radiation field. Management involves dietary modifications, proton pump inhibitors, viscous lidocaine for symptomatic relief, and narcotics for severe odynophagia. Esophagitis generally resolves within 2 to 4 weeks after completion of radiation therapy.

<image>A detailed annotated axial CT image showing target volume delineation for a stage IIIA (T2N2) NSCLC case. The GTV-primary (red) and GTV-node (orange, in station 7 and 4R) are contoured. The CTV (blue) shows 6 mm expansion from GTV respecting anatomic boundaries. Key organs at risk (bilateral lungs, heart, esophagus, spinal cord) are contoured with dose-volume histogram inset showing V20 lung at 28%, mean lung dose 16 Gy, and mean heart dose 12 Gy. The plan achieves 60 Gy to 95% of the PTV.</image>

<image>A survival curve reproduction from the PACIFIC trial showing overall survival for durvalumab versus placebo arms through 5-year follow-up. Key landmarks are annotated: median OS (47.5 vs. 29.1 months), 5-year OS rates (42.9% vs. 33.4%), and hazard ratio (0.72). A shaded area highlights the "PACIFIC gap" between curves that persists and widens over time.</image>

<image>A three-panel figure illustrating lessons from RTOG 0617. Panel A: Kaplan-Meier curves showing paradoxically worse OS with 74 Gy versus 60 Gy. Panel B: scatter plot showing the association between heart V5 (or heart V30) and overall survival, with higher cardiac dose correlating with worse outcomes. Panel C: dose-volume histogram comparison showing how reducing the cardiac dose (with IMRT/VMAT) improves the therapeutic ratio for locally advanced NSCLC.</image>

## Key Clinical Pearls

The standard radiation dose for locally advanced NSCLC is 60 Gy delivered in 30 fractions. The RTOG 0617 trial demonstrated that escalating the dose to 74 Gy worsens survival, likely due to increased cardiac toxicity. Involved-field radiation therapy (IFRT) is the preferred volume approach, as elective nodal irradiation adds toxicity without significantly reducing elective nodal failure rates. The PACIFIC trial is one of the most important practice-changing studies in radiation oncology, showing that consolidation durvalumab after concurrent CRT improves five-year overall survival by approximately 10% in absolute terms. Cardiac dose constraints are critical not only to prevent cardiac toxicity but also because heart dose independently predicts overall survival, as shown in RTOG 0617; thus, minimizing heart dose should be a priority in every treatment plan. Durvalumab should be started as soon as feasible after completing CRT, ideally within 1 to 42 days, and additional consolidation chemotherapy is no longer recommended.

## References
- Bradley JD et al. "Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study." *Lancet Oncol*. 2015;16(2):187-199.
- Antonia SJ et al. "Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC." *N Engl J Med*. 2018;379(24):2342-2350.
- Faivre-Finn C et al. "Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC -- an update from the PACIFIC trial." *J Thorac Oncol*. 2021;16(5):860-867.
- Chun SG et al. "Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial." *J Clin Oncol*. 2017;35(1):56-62.
- Albain KS et al. "Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial." *Lancet*. 2009;374(9687):379-386.